JNJ-26990990
JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression. JNJ-26990990 entered phase II clinical trials in October 2007.
Wikipage redirect
primaryTopic
JNJ-26990990
JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression. JNJ-26990990 entered phase II clinical trials in October 2007.
has abstract
JNJ-26990990 is a broad-spectr ...... ed to support its development.
@en
CAS number
877316-38-6
ChEBI
IUPAC name
3-[(Sulfamoylamino)methyl]-1-benzothiophene
@en
PubChem
thumbnail
Wikipage page ID
32,627,653
Wikipage revision ID
716,975,736
ChEMBL
ChemSpiderID
molecular weight
2.423179e+2
synonyms
Verifiedfields
verifiedrevid
444,297,842
Watchedfields
hypernym
comment
JNJ-26990990 is a broad-spectr ...... inical trials in October 2007.
@en
label
JNJ-26990990
@en